Plus Therapeutics CFO Buys RSUs & Options Amid CPT‑Code Expansion & Market Upside
Plus Therapeutics CFO’s insider buy of RSUs and options signals bullish confidence in the company’s CPT‑code expansion and future revenue growth.
4 minutes to read
Plus Therapeutics Inc